The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody
Interleukin (IL)-6 plays essential roles not only in the immune response, but also in haematopoiesis and the central nervous system. Deregulated production of IL-6 has been found in chronic inflammatory autoimmune diseases, such as rheumatoid arthritis (RA), systemic onset juvenile idiopathic arthri...
Gespeichert in:
| Veröffentlicht in: | Expert opinion on biological therapy 2005-05, Vol.5 (5), p.683-690 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 690 |
|---|---|
| container_issue | 5 |
| container_start_page | 683 |
| container_title | Expert opinion on biological therapy |
| container_volume | 5 |
| creator | Mihara, Masahiko Nishimoto, Norihiro Ohsugi, Yoshiyuki |
| description | Interleukin (IL)-6 plays essential roles not only in the immune response, but also in haematopoiesis and the central nervous system. Deregulated production of IL-6 has been found in chronic inflammatory autoimmune diseases, such as rheumatoid arthritis (RA), systemic onset juvenile idiopathic arthritis (soJIA), Crohn s disease (CD) and systemic lupus erythematosus (SLE). Furthermore, IL-6 activities can explain many symptoms of these diseases. More importantly, serum levels of IL-6 are correlated with disease activity. Based on these facts, the authors planned to develop a humanised anti-IL-6 receptor antibody, tocilizumab (previously known as MRA), as a therapeutic agent for these inflammatory autoimmune diseases. Tocilizumab is a neutralising antibody to suppress IL-6 signalling mediated by both membranous and soluble IL-6R. Clinical efficacy of tocilizumab in RA, soJIA, adult-onset Still s disease or CD patients has been discussed in this review. In all of these diseases, tocilizumab has improved the disease activity, suggesting that IL-6 plays an essential role in the pathogenesis of these diseases. |
| doi_str_mv | 10.1517/14712598.5.5.683 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_67899104</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20297949</sourcerecordid><originalsourceid>FETCH-LOGICAL-c497t-cbb9a3914f9b5b0f7209f30ebfc3a2c67002dfc92976e911f9d41d8eb0c5eb343</originalsourceid><addsrcrecordid>eNqFUE1P3DAQtSqqQqH3nlBO3LK1YyeO6ala0S8hcVnOlu2MFW-TeLEdofx7DLsV4gBoDjPS-5inh9BXglekJvwbYZxUtWhXdZ6mpR_QCeGMlbxpq6N8Z7h8xI_R5xi3GFdY1NUndExqQVnL6An6u-mhSD0EtVsKbws1J-_GcZ6g6FwEFSEWeinUlFzppgRhgPmfm8qmCGBgl3x4wrTvljP00aohwpfDPkW3P68269_l9c2vP-sf16VhgqfSaC0UFYRZoWuNLc-hLMWgraGqMg3PMTtrRCV4A4IQKzpGuhY0NjVoyugputj77oK_myEmObpoYBjUBH6OsuGtEAS_T6xw_iGYyES8J5rgYwxg5S64UYVFEiwfi5b_i5Z1nlx0lpwfvGc9QvcsODSbCd_3BDdZH0Z178PQyaSWwQcb1GRclPQN-8sX6h7UkHqjAsitn8OU-3092wOsoZ9r</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20297949</pqid></control><display><type>article</type><title>The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody</title><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><source>Taylor & Francis Journals Complete</source><creator>Mihara, Masahiko ; Nishimoto, Norihiro ; Ohsugi, Yoshiyuki</creator><creatorcontrib>Mihara, Masahiko ; Nishimoto, Norihiro ; Ohsugi, Yoshiyuki</creatorcontrib><description>Interleukin (IL)-6 plays essential roles not only in the immune response, but also in haematopoiesis and the central nervous system. Deregulated production of IL-6 has been found in chronic inflammatory autoimmune diseases, such as rheumatoid arthritis (RA), systemic onset juvenile idiopathic arthritis (soJIA), Crohn s disease (CD) and systemic lupus erythematosus (SLE). Furthermore, IL-6 activities can explain many symptoms of these diseases. More importantly, serum levels of IL-6 are correlated with disease activity. Based on these facts, the authors planned to develop a humanised anti-IL-6 receptor antibody, tocilizumab (previously known as MRA), as a therapeutic agent for these inflammatory autoimmune diseases. Tocilizumab is a neutralising antibody to suppress IL-6 signalling mediated by both membranous and soluble IL-6R. Clinical efficacy of tocilizumab in RA, soJIA, adult-onset Still s disease or CD patients has been discussed in this review. In all of these diseases, tocilizumab has improved the disease activity, suggesting that IL-6 plays an essential role in the pathogenesis of these diseases.</description><identifier>ISSN: 1471-2598</identifier><identifier>EISSN: 1744-7682</identifier><identifier>DOI: 10.1517/14712598.5.5.683</identifier><identifier>PMID: 15934843</identifier><language>eng</language><publisher>England: Ashley Publications Ltd</publisher><subject>Animals ; Antibodies - immunology ; Antibodies, Monoclonal - immunology ; Antibodies, Monoclonal, Humanized ; Autoimmune Diseases - immunology ; Autoimmune Diseases - therapy ; Humans ; IL-6 ; IL-6R ; inflammatory autoimmune diseases ; MRA ; Receptors, Interleukin-6 - antagonists & inhibitors ; Receptors, Interleukin-6 - immunology ; tocilizumab</subject><ispartof>Expert opinion on biological therapy, 2005-05, Vol.5 (5), p.683-690</ispartof><rights>Ashley Publications Ltd 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c497t-cbb9a3914f9b5b0f7209f30ebfc3a2c67002dfc92976e911f9d41d8eb0c5eb343</citedby><cites>FETCH-LOGICAL-c497t-cbb9a3914f9b5b0f7209f30ebfc3a2c67002dfc92976e911f9d41d8eb0c5eb343</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1517/14712598.5.5.683$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1517/14712598.5.5.683$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,59626,59732,60415,60521</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15934843$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mihara, Masahiko</creatorcontrib><creatorcontrib>Nishimoto, Norihiro</creatorcontrib><creatorcontrib>Ohsugi, Yoshiyuki</creatorcontrib><title>The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody</title><title>Expert opinion on biological therapy</title><addtitle>Expert Opin Biol Ther</addtitle><description>Interleukin (IL)-6 plays essential roles not only in the immune response, but also in haematopoiesis and the central nervous system. Deregulated production of IL-6 has been found in chronic inflammatory autoimmune diseases, such as rheumatoid arthritis (RA), systemic onset juvenile idiopathic arthritis (soJIA), Crohn s disease (CD) and systemic lupus erythematosus (SLE). Furthermore, IL-6 activities can explain many symptoms of these diseases. More importantly, serum levels of IL-6 are correlated with disease activity. Based on these facts, the authors planned to develop a humanised anti-IL-6 receptor antibody, tocilizumab (previously known as MRA), as a therapeutic agent for these inflammatory autoimmune diseases. Tocilizumab is a neutralising antibody to suppress IL-6 signalling mediated by both membranous and soluble IL-6R. Clinical efficacy of tocilizumab in RA, soJIA, adult-onset Still s disease or CD patients has been discussed in this review. In all of these diseases, tocilizumab has improved the disease activity, suggesting that IL-6 plays an essential role in the pathogenesis of these diseases.</description><subject>Animals</subject><subject>Antibodies - immunology</subject><subject>Antibodies, Monoclonal - immunology</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Autoimmune Diseases - immunology</subject><subject>Autoimmune Diseases - therapy</subject><subject>Humans</subject><subject>IL-6</subject><subject>IL-6R</subject><subject>inflammatory autoimmune diseases</subject><subject>MRA</subject><subject>Receptors, Interleukin-6 - antagonists & inhibitors</subject><subject>Receptors, Interleukin-6 - immunology</subject><subject>tocilizumab</subject><issn>1471-2598</issn><issn>1744-7682</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUE1P3DAQtSqqQqH3nlBO3LK1YyeO6ala0S8hcVnOlu2MFW-TeLEdofx7DLsV4gBoDjPS-5inh9BXglekJvwbYZxUtWhXdZ6mpR_QCeGMlbxpq6N8Z7h8xI_R5xi3GFdY1NUndExqQVnL6An6u-mhSD0EtVsKbws1J-_GcZ6g6FwEFSEWeinUlFzppgRhgPmfm8qmCGBgl3x4wrTvljP00aohwpfDPkW3P68269_l9c2vP-sf16VhgqfSaC0UFYRZoWuNLc-hLMWgraGqMg3PMTtrRCV4A4IQKzpGuhY0NjVoyugputj77oK_myEmObpoYBjUBH6OsuGtEAS_T6xw_iGYyES8J5rgYwxg5S64UYVFEiwfi5b_i5Z1nlx0lpwfvGc9QvcsODSbCd_3BDdZH0Z178PQyaSWwQcb1GRclPQN-8sX6h7UkHqjAsitn8OU-3092wOsoZ9r</recordid><startdate>20050501</startdate><enddate>20050501</enddate><creator>Mihara, Masahiko</creator><creator>Nishimoto, Norihiro</creator><creator>Ohsugi, Yoshiyuki</creator><general>Ashley Publications Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20050501</creationdate><title>The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody</title><author>Mihara, Masahiko ; Nishimoto, Norihiro ; Ohsugi, Yoshiyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c497t-cbb9a3914f9b5b0f7209f30ebfc3a2c67002dfc92976e911f9d41d8eb0c5eb343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Animals</topic><topic>Antibodies - immunology</topic><topic>Antibodies, Monoclonal - immunology</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Autoimmune Diseases - immunology</topic><topic>Autoimmune Diseases - therapy</topic><topic>Humans</topic><topic>IL-6</topic><topic>IL-6R</topic><topic>inflammatory autoimmune diseases</topic><topic>MRA</topic><topic>Receptors, Interleukin-6 - antagonists & inhibitors</topic><topic>Receptors, Interleukin-6 - immunology</topic><topic>tocilizumab</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mihara, Masahiko</creatorcontrib><creatorcontrib>Nishimoto, Norihiro</creatorcontrib><creatorcontrib>Ohsugi, Yoshiyuki</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Expert opinion on biological therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mihara, Masahiko</au><au>Nishimoto, Norihiro</au><au>Ohsugi, Yoshiyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody</atitle><jtitle>Expert opinion on biological therapy</jtitle><addtitle>Expert Opin Biol Ther</addtitle><date>2005-05-01</date><risdate>2005</risdate><volume>5</volume><issue>5</issue><spage>683</spage><epage>690</epage><pages>683-690</pages><issn>1471-2598</issn><eissn>1744-7682</eissn><abstract>Interleukin (IL)-6 plays essential roles not only in the immune response, but also in haematopoiesis and the central nervous system. Deregulated production of IL-6 has been found in chronic inflammatory autoimmune diseases, such as rheumatoid arthritis (RA), systemic onset juvenile idiopathic arthritis (soJIA), Crohn s disease (CD) and systemic lupus erythematosus (SLE). Furthermore, IL-6 activities can explain many symptoms of these diseases. More importantly, serum levels of IL-6 are correlated with disease activity. Based on these facts, the authors planned to develop a humanised anti-IL-6 receptor antibody, tocilizumab (previously known as MRA), as a therapeutic agent for these inflammatory autoimmune diseases. Tocilizumab is a neutralising antibody to suppress IL-6 signalling mediated by both membranous and soluble IL-6R. Clinical efficacy of tocilizumab in RA, soJIA, adult-onset Still s disease or CD patients has been discussed in this review. In all of these diseases, tocilizumab has improved the disease activity, suggesting that IL-6 plays an essential role in the pathogenesis of these diseases.</abstract><cop>England</cop><pub>Ashley Publications Ltd</pub><pmid>15934843</pmid><doi>10.1517/14712598.5.5.683</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-2598 |
| ispartof | Expert opinion on biological therapy, 2005-05, Vol.5 (5), p.683-690 |
| issn | 1471-2598 1744-7682 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67899104 |
| source | MEDLINE; Taylor & Francis Medical Library - CRKN; Taylor & Francis Journals Complete |
| subjects | Animals Antibodies - immunology Antibodies, Monoclonal - immunology Antibodies, Monoclonal, Humanized Autoimmune Diseases - immunology Autoimmune Diseases - therapy Humans IL-6 IL-6R inflammatory autoimmune diseases MRA Receptors, Interleukin-6 - antagonists & inhibitors Receptors, Interleukin-6 - immunology tocilizumab |
| title | The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T06%3A03%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20therapy%20of%20autoimmune%20diseases%20by%20anti-interleukin-6%20receptor%20antibody&rft.jtitle=Expert%20opinion%20on%20biological%20therapy&rft.au=Mihara,%20Masahiko&rft.date=2005-05-01&rft.volume=5&rft.issue=5&rft.spage=683&rft.epage=690&rft.pages=683-690&rft.issn=1471-2598&rft.eissn=1744-7682&rft_id=info:doi/10.1517/14712598.5.5.683&rft_dat=%3Cproquest_pubme%3E20297949%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20297949&rft_id=info:pmid/15934843&rfr_iscdi=true |